White House looks to CMMI to test new ways to lower drug prices
C&M Health Law
NOVEMBER 7, 2022
The EO comes two months after the president signed the Inflation Reduction Act (IRA) which promises to lower the cost of prescription drugs for many Medicare beneficiaries. This is not the first time that the White House will try to leverage CMMI’s testing authority to create models that would lower drug costs in Medicare.
Let's personalize your content